

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHANGE OF NON-EXECUTIVE DIRECTOR

The Board announces that, with effect from 9 February 2024:

1. Mr. Gong has resigned as a non-executive director of the Company; and
2. Mr. Feng has been appointed as a non-executive director of the Company.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of Everest Medicines Limited (the “**Company**”) announces that Mr. Yubo Gong (“**Mr. Gong**”) has resigned as a non-executive director of the Company with effect from 9 February 2024 to devote more time to his other business endeavours.

Mr. Gong has confirmed that he has no disagreement with the Board and that there are no matters that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) relating to his resignation.

The Board wishes to express its sincere gratitude to Mr. Gong for his invaluable contributions to the Company during his tenure of service.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board announces that Mr. Honggang Feng (“**Mr. Feng**”) has been appointed as a non-executive director of the Company with effect from 9 February 2024.

The biographical details of Mr. Feng are set out below:

Mr. Feng, aged 59, has more than 35 years of experience in the healthcare industry. He is currently a senior advisor of CBC Group, a controlling shareholder of the Company, where he assists in portfolio management and is responsible for the post-investment management. He was the president of Simcere Pharmaceutical Group Limited (stock code: 2096.hk) from January 2015 to November 2019, and held other leadership positions in Simcere from 1994 to 2007, including as a director of biomedical department, vice president of its research institute and as a director of marketing department. From August 2007 to October 2014, Mr. Feng was the general manager of Shihuida Pharma Group. Mr. Feng started his career as an internist and an endocrinologist in different hospitals.

Mr. Feng received his medical education from Yangzhou Medical College (now known as Medical School, Yangzhou University) in 1982 and obtained a Master of Medicine from China Medical University in 1989.

Mr. Feng has entered into an appointment letter with the Company for a term of three years from 9 February 2024, subject to (i) retirement from office and re-election at the first annual general meeting of the Company after his appointment and (ii) retirement by rotation and re-election at least once every three years, in accordance with the articles of association of the Company and the corporate governance code set out in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). According to the terms of Mr. Feng’s appointment, Mr. Feng will not receive any remuneration or benefits in his capacity as a non-executive Director but is entitled to the reimbursement of all reasonable out-of-pocket expenses incurred in the performance of his duties in connection with the business of the Company.

Save as disclosed above, as at the date of this announcement, Mr. Feng has confirmed that he does not hold (i) any other position with the Company or other members of the Group; (ii) any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; or (iii) any other major appointments and professional qualifications.

Save as disclosed above, as at the date of this announcement, Mr. Feng has also confirmed that he does not have (i) any relationship with any director, senior management or substantial shareholder or controlling shareholder of the Company; or (ii) any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, there is no other information to be disclosed pursuant to any of the requirements under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules nor are there other matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange relating to Mr. Feng’s appointment.

The Board would like to express its warmest welcome to Mr. Feng on his appointment.

By order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, 9 February 2024

As at the date of this announcement, the Board comprises Mr. Wei Fu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. William Ki Chul Cho and Mr. Honggang Feng as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.